2023
Racial/ethnic disparities in PM2.5-attributable cardiovascular mortality burden in the United States
Ma Y, Zang E, Opara I, Lu Y, Krumholz H, Chen K. Racial/ethnic disparities in PM2.5-attributable cardiovascular mortality burden in the United States. Nature Human Behaviour 2023, 7: 2074-2083. PMID: 37653149, PMCID: PMC10901568, DOI: 10.1038/s41562-023-01694-7.Peer-Reviewed Original ResearchConceptsNon-Hispanic White peopleCVD deathMortality burdenNon-Hispanic black peopleCardiovascular disease mortality ratesDisease mortality ratesNon-Hispanic blacksRace/ethnicityMortality rateLong-term exposureWhite peopleEthnic disparitiesHealth benefitsHispanic peopleSignificant differencesBurdenDeathUS countiesEthnic groupsAbsolute disparityAssociationExposureEthnic minoritiesDisparitiesAmbient fine particulate matter (PM2.5) concentrations
2021
SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut
Mahajan S, Caraballo C, Li SX, Dong Y, Chen L, Huston SK, Srinivasan R, Redlich CA, Ko AI, Faust JS, Forman HP, Krumholz HM. SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut. The American Journal Of Medicine 2021, 134: 812-816.e2. PMID: 33617808, PMCID: PMC7895685, DOI: 10.1016/j.amjmed.2021.01.020.Peer-Reviewed Original ResearchConceptsInfection hospitalization rateInfection fatality rateHospitalization ratesFatality rateSeroprevalence estimatesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodiesSARS-CoV-2 antibodiesConnecticut Hospital AssociationNon-Hispanic black peopleProportion of deathsCoronavirus disease 2019Total infected individualsTotal hospitalizationsAdverse outcomesNon-congregate settingsHigh burdenDisease 2019Prevalence studyMost subgroupsInfected individualsHospitalizationOlder peopleHospital AssociationConnecticut DepartmentDeathSuicide Deaths During the COVID-19 Stay-at-Home Advisory in Massachusetts, March to May 2020
Faust JS, Shah SB, Du C, Li SX, Lin Z, Krumholz HM. Suicide Deaths During the COVID-19 Stay-at-Home Advisory in Massachusetts, March to May 2020. JAMA Network Open 2021, 4: e2034273. PMID: 33475750, PMCID: PMC7821026, DOI: 10.1001/jamanetworkopen.2020.34273.Peer-Reviewed Original Research
2017
Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease
Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk Trajectories of Readmission and Death in the First Year after Hospitalization for Chronic Obstructive Pulmonary Disease. American Journal Of Respiratory And Critical Care Medicine 2017, 197: 1009-1017. PMID: 29206052, PMCID: PMC5909167, DOI: 10.1164/rccm.201709-1852oc.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseSame respective groupsObstructive pulmonary diseaseVentilator supportPulmonary diseaseRisk of readmissionRisk of hospitalizationGeneral elderly populationGeneral Medicare populationRisk of deathDaily riskRespective groupsReadmission ratesHospital readmissionAbsolute riskMedicare populationReadmissionElderly populationMedicare beneficiariesHospitalizationClinical servicesFirst monthProlonged riskDeathLongitudinal outcomes
2010
Telemonitoring in Patients with Heart Failure
Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, Krumholz HM. Telemonitoring in Patients with Heart Failure. New England Journal Of Medicine 2010, 363: 2301-2309. PMID: 21080835, PMCID: PMC3237394, DOI: 10.1056/nejmoa1010029.Peer-Reviewed Original ResearchConceptsPrimary end pointUsual care groupSecondary end pointsHeart failureEnd pointHeart failure outcomesNumber of hospitalizationsTelephone-based interactive voice response systemUsual careAdverse eventsPatient's clinicianMedian ageCare groupLarge trialsInteractive voice response systemPatientsSmall studyVoice response systemNumber of daysHospitalizationReadmissionTelemonitoringSignificant differencesCliniciansDeath
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2007
The Impact of Venous Thromboembolism on Risk of Death or Hemorrhage in Older Cancer Patients
Gross CP, Galusha DH, Krumholz HM. The Impact of Venous Thromboembolism on Risk of Death or Hemorrhage in Older Cancer Patients. Journal Of General Internal Medicine 2007, 22: 321-326. PMID: 17356962, PMCID: PMC1824718, DOI: 10.1007/s11606-006-0019-x.Peer-Reviewed Original ResearchConceptsRisk of deathOlder cancer patientsConcomitant venous thromboembolismVenous thromboembolismMajor hemorrhageCancer patientsCancer typesCancer diagnosisMedicare administrative claims dataPrevalence of VTEEnd Results cancer registryRetrospective cohort studyAdministrative claims dataCohort studyCancer RegistryInvasive cancerExcess riskMost cancer typesCancer stageClaims dataHemorrhagePatientsSociodemographic factorsPotential mediatorsDeath
2005
Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002
Vaccarino V, Rathore SS, Wenger NK, Frederick PD, Abramson JL, Barron HV, Manhapra A, Mallik S, Krumholz HM. Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002. New England Journal Of Medicine 2005, 353: 671-682. PMID: 16107620, PMCID: PMC2805130, DOI: 10.1056/nejmsa032214.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAspirinBlack PeopleCoronary AngiographyFemaleHealth Services AccessibilityHospital MortalityHumansLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPlatelet Aggregation InhibitorsProcess Assessment, Health CareQuality of Health CareRisk FactorsSex FactorsUnited StatesWhite PeopleConceptsUse of aspirinMyocardial infarctionReperfusion therapyCoronary angiographyRacial differencesTreatment of patientsHospital deathHospital mortalityMultivariable adjustmentUnadjusted analysesNational registryInfarctionWhite womenAspirinAngiographyTherapyWhite menSexPatientsBlack womenSex differencesParticular treatmentBlack menWomenDeath
2004
Management of implantable cardioverter defibrillators in end-of-life care.
Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Annals Of Internal Medicine 2004, 141: 835-8. PMID: 15583224, DOI: 10.7326/0003-4819-141-11-200412070-00006.Peer-Reviewed Original ResearchThe association of 6-minute walk performance and outcomes in stable outpatients with heart failure.
Curtis JP, Rathore SS, Wang Y, Krumholz HM. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal Of Cardiac Failure 2004, 10: 9-14. PMID: 14966769, DOI: 10.1016/s1071-9164(03)00705-x.Peer-Reviewed Original ResearchThe association of 6-minute walk performance and outcomes in stable outpatients with heart failure
Curtis J, Rathore S, Wang Y, Krumholz H. The association of 6-minute walk performance and outcomes in stable outpatients with heart failure. Journal Of Cardiac Failure 2004, 10: 9-14. DOI: 10.1016/j.cardfail.2003.08.010.Peer-Reviewed Original ResearchHeart failureWalk testStable outpatientsDigitalis Investigation Group trialRisk of deathCause mortalityIdentifies patientsMultivariable analysisPrognostic valuePrognostic informationGroup trialsWalk performancePatientsTest distanceMortalityDeathOutpatientsOutcomesFailureAssociationBackgroundWeTrialsMonths
2003
The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure
Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portnay EL, Marshalko SJ, Radford MJ, Krumholz HM. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. Journal Of The American College Of Cardiology 2003, 42: 736-742. PMID: 12932612, DOI: 10.1016/s0735-1097(03)00789-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionVentricular ejection fractionHeart failureCause of deathLVEF groupHF patientsMultivariable adjustmentEjection fractionStable outpatientsAssociation of LVEFHigher left ventricular ejection fractionLow left ventricular ejection fractionDigitalis Investigation Group trialHigh LVEF groupStable HF patientsPrognostic importanceAbsolute riskPrognostic indicatorSinus rhythmGroup trialsMortality ratePatientsMortalityDeathOutpatientsOutcomes in heart failure patients with preserved ejection fraction Mortality, readmission, and functional decline
Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction Mortality, readmission, and functional decline. Journal Of The American College Of Cardiology 2003, 41: 1510-1518. PMID: 12742291, DOI: 10.1016/s0735-1097(03)00185-2.Peer-Reviewed Original ResearchConceptsDepressed ejection fractionRisk of readmissionEjection fractionHeart failureFunctional declineHeart failure patientsHF patientsFailure patientsHospital dischargeHospital readmissionIndependent predictorsClinical outcomesPoor prognosisFunctional statusClinical covariatesClinical trajectoriesReadmissionLower riskPatientsConsiderable burdenCombined outcomeNatural historyMortalityDeathOutcomesWorsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure?
Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? Journal Of Cardiac Failure 2003, 9: 13-25. PMID: 12612868, DOI: 10.1054/jcaf.2003.3.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCohort StudiesConnecticutCreatinineFemaleFollow-Up StudiesHeart FailureHospitalizationHumansKidney DiseasesKidney Function TestsMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProspective StudiesRisk FactorsSensitivity and SpecificityStatistics as TopicStroke VolumeSurvival AnalysisConceptsCreatinine elevationRenal functionHeart failureAdverse outcomesRisk of deathNumber of patientsMagnitude of riskBaseline creatinineProspective cohortRisk factorsFunctional declineHigh riskPatientsCreatinineMortalityHospitalizationDeathDlImportant predictorRiskElevationMeaningful changeMaximum specificityOutcomesBetter definition